Israeli PRs

Nanox Imaging Ltd. (“Nanox” or the “Company”, NASDAQ: NNOX), a leader in innovative medical imaging technology, today announced that its wholly owned subsidiary, USARAD Holdings, Inc. (“USARAD”), is expanding its existing collaboration with AZmed, a medical imaging AI company specializing in AI-powered X-ray analysis, to further integrate AZmed’s X-ray AI solutions into USARAD’s radiology workflows through Nanox Marketplace.

AZmed’s Rayvolve AI suite covers eight FDA-cleared findings across musculoskeletal and chest X-rays. AZtrauma is FDA-cleared as computer-assisted detection and diagnosis software for fractures, dislocations and joint effusions in adult and pediatric patients aged two and older. AZchest is FDA-cleared to assist radiologists in detecting and localizing pneumothorax, pleural effusion, consolidation and increased cardiothoracic ratio on frontal chest radiographs. Separately, Rayvolve LN is FDA-cleared to assist in detecting pulmonary nodules. Early this year, the Rayvolve AI suite was evaluated in the peer-reviewed journal Radiography in the largest published multicenter study of X-ray AI to date, covering 258,373 X-rays from 100 medical centers across 26 countries and five continents.

USARAD has worked with AZmed since 2023 and already uses AZmed’s AI, starting with AZtrauma for acute musculoskeletal trauma and, in 2026, extending to AZchest for chest X-rays. Under this agreement the suite will be further integrated into USARAD’s radiology workflows, which support a large network of radiologists across the U.S., with the goal of helping them prioritize and read studies more efficiently.

AZmed’s AI will be delivered through Nanox Marketplace, which will enable automated study routing and DICOM transmission between AZmed’s AI and connected facilities on OnePacs, USARAD’s cloud PACS platform, so AI results reach radiologists without leaving the system they already read in.

“We have valued the results of our work with AZmed, so we are pleased to expand our collaboration,” said Elli Yuz, Chief Executive Officer of USARAD Holdings, Inc. “Making AZmed’s FDA-cleared X-ray AI available through Nanox Marketplace and further integrated into our workflows will help our radiologists prioritize and read studies more efficiently.”

“AI in radiology has moved beyond point solutions, with one algorithm per finding from a different vendor,” said Julien Vidal, Chief Executive Officer of AZmed. “The value now lies in end-to-end suites with FDA-cleared capabilities and published clinical evidence. A network reading at USARAD’s scale is exactly where this value becomes clear.”

Schedule a meeting with Nanox (booth #1759) and AZmed (booth #5509) at RSNA 2026: Nanox at nanox.vision/rsna2026; AZmed at azmed.co/events